	US 12,258,388 B2
	Compositions and methods comprising SFRP2 antagonists
Nancy Demore, Mount Pleasant, SC (US); and Cam Patterson, Little Rock, AR (US)
Assigned to The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
Filed by The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
Filed on Jan. 12, 2024, as Appl. No. 18/412,245.
Application 18/412,245 is a division of application No. 17/547,550, filed on Dec. 10, 2021, granted, now 11,873,333.
Claims priority of provisional application 63/124,345, filed on Dec. 11, 2020.
Prior Publication US 2024/0190949 A1, Jun. 13, 2024
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)

CPC C07K 16/18 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/3015 (2013.01); C07K 16/303 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01)]

5 Claims

1. A method of treating cancer in a patient, the method comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of a humanized anti-secreted frizzled-related protein 2 (SFRP2) antibody or antigen binding fragment thereof which binds SFRP2, wherein said humanized antibody or antigen binding fragment thereof comprises a variable heavy (VH) chain polypeptide and a variable light (VL) chain polypeptide comprising the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 9, respectively, and a pharmaceutically acceptable excipient.